-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 25, 2021, Oncopeptides AB announced that its peptide-conjugated drug Pepaxto (melphalan flufenamide) has achieved positive results in a phase 3 clinical trial for the treatment of relapsed/refractory multiple myeloma (R/R MM).
The Phase 3 clinical trial project was launched in 2017 and enrolled 495 patients from 21 countries to evaluate the efficacy and safety of Pepaxto in the treatment of patients with R/R MM compared with pomalidomide.
Pepaxto is a "first-in-class" peptide-conjugated drug that couples alkylating agents with peptides that target aminopeptidase.
MM is a malignant blood cancer caused by abnormal proliferation of plasma cells in the bone marrow.
Note: The original text has been deleted
Reference materials:
[1] Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma.
